Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

PER® Postgame: Breaking Down the Latest Data and Updates in Anemia of Chronic Kidney Disease – Fall 2021 Nephrology Meeting Takeaways

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

Chronic kidney disease (CKD) is associated with a markedly higher risk of anemia, and this CKD-associated anemia is linked, in turn, to lower quality of life and increased morbidity and mortality. Despite conventional treatments for CKD-related anemia, unmet needs remain in the optimal management of this complication.

This program will feature experts from primary care and nephrology, who will discuss emerging targets in the pathophysiology of anemia in CKD, opportunities for improved diagnosis and management of CKD-related anemia in primary care and nephrology settings, and fresh data on a novel class of investigational agents—all in a lively new format.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward nephrologists and primary care physicians. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of CKD and anemia are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review the clinical burden of anemia in patients with CKD
  • Discuss the pathophysiology of anemia in CKD, including therapeutic targets
  • Apply current assessment strategies to accurately diagnose patients with anemia and CKD based on clinical presentation
  • Describe safety and efficacy data on new and emerging agents for patients with CKD-associated anemia

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.


Stephen Brunton, MD, FAAFP, CDCES
Stephen Brunton, MD, FAAFP, CDCES
Executive Director
Primary Care Metabolic Group
Winnsboro, SC
Associate Clinical Professor
Touro University College of Osteopathic Medicine
Vallejo, CA

Disclosures: Consultant: Abbott, AstraZeneca, Bayer Healthcare Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, Sanofi Aventis, Boehringer Ingelheim. Speakers Bureau: Abbott, Astra Zeneca, Bayer Healthcare Pharmaceuticals, Xeris Biopharma, Novo Nordisk, Sanofi Aventis, Boehringer Ingelheim; Stock/Shareholder: Paracrine (stock options).


Rajiv Agarwal, MD
Rajiv Agarwal, MD
Professor of Medicine
Indiana University School of Medicine
Indianapolis, IN

Disclosures: Consultant: Akebia Therapeutics, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, DiaMedica Therapeutics, Janssen Pharmaceuticals, Reata Pharmaceuticals, Relypsa Inc. Data Safety Board: Chinook Therapeutics, Vertex Pharmaceuticals.

Eden Miller, D.O. Diplomate ABOM
Eden Miller, D.O. Diplomate ABOM
Founder of Diabetes and Obesity Care LLC
Bend, OR

Disclosures: Grant/Research support: Pendulum Therapeutics, Abbott Diabetes Care Inc. Consultant: Eli Lilly & Company, Novo Nordisk, Boehringer Ingelheim, Abbott Diabetes Care Inc. Other: ADA II Steering Committee.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By